Fig. 5

Antitumor effects of hNVs@Flu-EGCGin vivo. (A) Diagram illustrating the timetable of therapy following the C57BL/6 mouse RM-1 prostate tumor model. (B) Individual and (C) mean tumor growth patterns among varied groups (n = 5). (D) The body weight of mice in different groups (n = 5). (E) Survival plots of RM-1 tumor-carrying mice subjected to different therapies as noted. (F) Exemplary pictures exhibiting Ki-67 and TUNEL labeling of tumor sections carried out through immunohistochemistry. Scale bar, 100 μm. All data are expressed as mean ± S.D. NS: no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001